Correlation between in vitro peptide binding profiles and cellular activities for estrogen receptor-modulating compounds

被引:56
作者
Iannone, MA
Simmons, CA
Kadwell, SH
Svoboda, DL
Vanderwall, DE
Deng, SJ
Consler, TG
Shearin, J
Gray, JG
Pearce, KH
机构
[1] GlaxoSmithKline, Dept Gene Express & Prot Biochem, Discovery Res, Res Triangle Pk, NC 27709 USA
[2] GlaxoSmithKline, Dept Cheminformat, Discovery Res, Res Triangle Pk, NC 27709 USA
关键词
D O I
10.1210/me.2003-0432
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Numerous biochemical and structural studies have shown that the conformation of the estrogen receptor alpha (ERalpha) can be influenced by ligand binding. In turn, the conformational state of ERalpha affects the ability of the receptor to interact with a wide variety of protein accessory factors. To globally investigate ligand-based cofactor recruitment activities of ERalpha, we have applied a flow cytometric multiplexed binding assay to determine the simultaneous binding of ERalpha to over 50 different peptides derived from both known cofactor proteins and random peptide phage display. Using over 400 ERalpha-binding compounds, we have observed that the multiplexed in vitro peptide-binding profiles are distinct for a number of compounds and that these profiles can predict the effect that ERalpha ligands have on various cellular activities. These cell-based activities include transcriptional regulation at an estrogen response element, MCF-7 cell proliferation, and Ishikawa endometrial cell stimulation. The majority of the compound-induced diversity in the peptide profiling assay is provided by the unique phage display peptides. Importantly, some of these peptides show a sequence relationship with the corepressor motif, suggesting that peptides identified via phage display might represent natural binding partners of ERalpha. These in vitro: cellular correlations may in part explain tissue-specific activities of ERalpha-modulating compounds.
引用
收藏
页码:1064 / 1081
页数:18
相关论文
共 65 条
[1]   Signal transducers and activators of transcription as downstream targets of nongenomic estrogen receptor actions [J].
Björnström, L ;
Sjöberg, M .
MOLECULAR ENDOCRINOLOGY, 2002, 16 (10) :2202-2214
[2]   Ligands specify coactivator nuclear receptor (NR) box affinity for estrogen receptor subtypes [J].
Bramlett, KS ;
Wu, YF ;
Burris, TP .
MOLECULAR ENDOCRINOLOGY, 2001, 15 (06) :909-922
[3]   Molecular basis of agonism and antagonism in the oestrogen receptor [J].
Brzozowski, AM ;
Pike, ACW ;
Dauter, Z ;
Hubbard, RE ;
Bonn, T ;
Engstrom, O ;
Ohman, L ;
Greene, GL ;
Gustafsson, JA ;
Carlquist, M .
NATURE, 1997, 389 (6652) :753-758
[4]  
Chang CY, 1999, MOL CELL BIOL, V19, P8226
[5]  
Connor CE, 2001, CANCER RES, V61, P2917
[6]  
Deng S J, 1995, Methods Mol Biol, V51, P329
[7]   SIMULTANEOUS RANDOMIZATION OF ANTIBODY CDRS BY A SYNTHETIC LIGASE CHAIN-REACTION STRATEGY [J].
DENG, SJ ;
MACKENZIE, CR ;
NARANG, SA .
NUCLEIC ACIDS RESEARCH, 1993, 21 (18) :4418-4419
[8]   Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): Multiple motifs with different binding specificities [J].
Ding, XF ;
Anderson, CM ;
Ma, H ;
Hong, H ;
Uht, RM ;
Kushner, PJ ;
Stallcup, MR .
MOLECULAR ENDOCRINOLOGY, 1998, 12 (02) :302-313
[9]  
Edmunds JSG, 1997, NEUROTOXICOLOGY, V18, P525
[10]   Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site [J].
Fairbrother, WJ ;
Christinger, HW ;
Cochran, AG ;
Fuh, C ;
Keenan, CJ ;
Quan, C ;
Shriver, SK ;
Tom, JYK ;
Wells, JA ;
Cunningham, BC .
BIOCHEMISTRY, 1998, 37 (51) :17754-17764